ExThera Medical Announces Creation of European Subsidiary
ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary.
Carla brings more than 30 years of experience in clinical research and the commercialization of new medical devices in the European market to ExThera Medical, where she will oversee the strategic direction for ExThera’s European operations.
“The establishment of our European subsidiary is an exciting milestone as we prepare for commercialization,” said Robert Ward, President and CEO of ExThera Medical. “Carla has a distinguished track record in medical device development and commercialization, including overseeing clinical research, regulatory affairs, quality assurance, and operations. As CEO of her company, Meditech, she successfully supported the rapid clinical adoption of many new medical devices. Carla’s strategic leadership will be invaluable as we continue our clinical research in Europe and build our operations and infrastructure for commercialization.”
Carla was most recently interim CEO and board chairwoman of Vimecon GmbH, which provides laser-based treatment of atrial fibrillation. In 2000, she founded MediTech Strategic Consultants in the Netherlands, a contract research organization for medical devices, and served as the company’s CEO until the company was acquired by MedPace in 2012. She has served as a board director for Shape Memory Therapeutics, Replication Medical, and as advisor to Greenhills Ventures. Carla has also been active in the EU Commission and Dutch Standardization Institute and has received several industry awards recognizing her accomplishments including the Next Women 100 Award in 2013, recognizing her as one of the 100 most influential business women in the Netherlands, and the Federation Businesswomen Award, as the best international female entrepreneur in 2010.
“Seraph holds incredible promise to transform the treatment of potentially lethal bloodstream infections,” said Kikken-Jussen. “Traditional treatments are costly and often result in poor outcomes, while contributing to drug resistance. They can also require lengthy hospital stays, and frequently fail to prevent patients from developing sepsis. I am eager to drive the completion of ongoing clinical trials in Europe and prepare for the commercialization of Seraph.”
Interim safety and performance data from the ongoing European clinical trial of the ‘Seraph® 100’ Blood Filter will be presented on March 20, 2018 at the International Symposium on Intensive Care and Emergency Medicine Congress in Brussels by Prof. Jan Kielstein of Academic Teaching Hospital in Braunschweig, Germany.
ExThera Medical is focused on developing easy-to-use devices for the rapid treatment of life-threatening/drug-resistant bloodstream infections, especially in the face of rising incidence rates and the spread of drug-resistant pathogens worldwide. The company’s Seraph ® Microbind ® Affinity Blood Filters can remove a broad range of sepsis-causing bacteria, viruses and toxins from whole blood. The technologies are currently under evaluation in a promising European clinical trial and recently designated by FDA for inclusion in their Expedited Access Pathway (EAP) program (Seraph 100). EAP designation is granted to devices that have the potential to satisfy unmet clinical needs in the prevention of fatal or debilitating diseases.
About ExThera Medical
Based in Martinez, Calif., ExThera Medical is a privately held medical device company developing innovative, single-use blood filters capable of capturing and removing a broad range of bacteria, viruses, parasites, toxins or other harmful substances from whole blood. The company develops therapeutic products to treat patients in the hospital or clinic, or on the battlefield. Led by an accomplished management team with extensive experience in blood-contacting devices and biomaterials, the company has strong patent protection and a growing body of data from independent laboratory studies, in addition to its participation in DARPA’s Dialysis-Like Therapeutics program. For more information, visit www.extheramedical.com.
Disclaimer: All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
Caution: The Seraph® Microbind® Affinity Blood Filter is currently undergoing clinical evaluation and is not available for commercial sale.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
OpenGate Capital Signs Exclusivity Agreement to Sell NAKAN to Westlake Chemical Corporation25.9.2018 15:00 | Tiedote
OpenGate Capital, a global private equity firm, announced today that it has signed an exclusivity agreement with Westlake Chemical Corporation (NYSE: WLK), pursuant to which Westlake has made a binding offer to acquire NAKAN, a global PVC compounding solutions business headquartered in Reims, France. The transaction is valued at $265 million and is anticipated to be completed by early 2019. NAKAN has eight production facilities located in China, France, Germany, Italy, Japan, Mexico, Spain and Vietnam, as well as a world-class research facility in France and application laboratory in the United States. NAKAN products are used in a wide-variety of applications by customers in the automotive, building and construction, and medical industries. OpenGate Capital acquired NAKAN in 2015, through the acquisition of Ivy Group, during the firm’s pre-fund, legacy investment period. Ivy Group, formerly known as Kem One Innovative Vinyls, was acquired through a French administration process that or
The 2018 IDN World Report Findings Show Negative IDN Growth in 201725.9.2018 14:24 | Tiedote
The 2018 IDN World Report findings have been published to idnworldreport.eu. The major findings from the report are: As at December 2017, 7.5 million IDNs were registered, a drop of 14% since December 2016. A major factor in the reduction in global IDN numbers was a change of policy by the Vietnam ccTLD, which resulted in a loss of nearly 1 million .vn second level IDNs. Excluding the impact of .vn, the underlying trend is negative growth of -5%, distributed mainly across second level ccTLDs. IDNs comprise 2% of the world’s domains, a percentage that has remained fairly static since at least 2012. The data in this report include IDNs across both ccTLDs and gTLDs, both at the first and second level. Distribution patterns of IDN registrations are different from those of traditional, ASCII domain names. IDN registrations are highest in Asia and Pacific region. The script of IDNs registered throughout the world strongly correlate to the languages spoken in different countries and territori
Michael Kors Holdings Limited to Be Renamed Capri Holdings Limited25.9.2018 14:00 | Tiedote
Michael Kors Holdings Limited (NYSE:KORS), a global fashion luxury group, announced today that a definitive agreement has been signed to acquire all of the outstanding shares of Italian luxury fashion house Gianni Versace S.p.A. for a total enterprise value of Euro 1.83 billion or approximately US$2.12 billion. Versace, long recognized as one of the world’s leading luxury fashion companies, is synonymous with Italian glamour and style. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005557/en/ L-R: Jonathan Akeroyd, Donatella Versace, John D. Idol. (Photo: Rahi Rezvani) John D. Idol, Chairman and Chief Executive Officer of Michael Kors Holdings Limited, said, “The acquisition of Versace is an important milestone for our group. Versace was founded in 1978. For over 40 years, Versace has represented the epitome of Italian fashion luxury, a testament to the brand’s timeless heritage. We are excited to have Versace as part
2018 UL International Crown to Be Staged in Incheon October 4-725.9.2018 13:00 | Tiedote
2018 UL International Crown will be held October 4-7 at Jack Nicklaus Golf Club Korea in Songdo, Incheon Metropolitan City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005024/en/ 2018 UL International Crown will be held October 4-7 at Jack Nicklaus Golf Club Korea in Songdo, Incheon Metropolitan City. Incheon Metropolitan City is not sparing any effort to support the event as an Ambassador Partner. The most high-profile biennial golf tournament on the LPGA Tour, the third UL International Crown to take place with the second held in Chicago in 2016. 32 players from the eight countries will compete in the four-day match-play event for the “Crown.” (Graphic: Business Wire) The most high-profile biennial golf tournament on the LPGA Tour, a first-of-its-kind team match-play competition featuring the best women golfers from the top eight countries around the world, is being played outside the United States for the first t
Abu Dhabi's Fund Agreed Friendly TOB with MINDOL25.9.2018 12:59 | Tiedote
Abu Dhabi Dubai STOB Series 22 Investment Limited Partnership (”AbuDhabi22”as follows) and MINDOL HOLDINGS LIMITED (”MINDOL” as follows) which is listed on the Coinsuper Exchange in Hong Kong (https://www.coinsuper.com) agreed AbuDhabi22 to get 33% of crypto currency MINDOL (MIN)(http://mindol.net) that MINDOL issued by TOB. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005523/en/ The world audition of the Hollywood movie "TO DO & DIE" planned to be released worldwide in 2020! (Graphic: Business Wire) Strengthen strategic partnership with MINDOL by implementing TOB. Both of companies chose TOB as strategic approach to make a purchase at a stable price because acquisition price that AbuDhabi22 planned would be expected to significantly exceed with purchases via regular exchanges. TOB STAGE 1 has already finished and now TOB is being implemented at the purchase price of TOB STAGE 2. As a management vision for 2019, MIND
Brentwood Borough Council Stays Ahead of the Game with UniPrint/Azure Cloud Print Solution25.9.2018 12:18 | Tiedote
UniPrint.net announced today their successful secure cloud print deployment with Brentwood Borough Council in Essex, UK. In 2016, the Council released a report entitled “Vision for Brentwood, 2016-2019”. In it, they outlined their goals to better the lives of their constituents, and those goals included reducing costs and streamlining services. After examining their existing infrastructure, they made the decision to become the 1st UK council to move 100% of its systems and infrastructure to the cloud. “We wanted to create a very easy delivery of people’s desktops no matter where they were, whether it was a coffee shop, their home, or one of our sites,” said Tim Huggins, ICT Manager at Brentwood Borough Council. This presented a multitude of challenges, but one of the biggest was printing. “We approached our common provider,” said Huggins. “But it became quite evident very quickly that they had no solution, and we were way ahead of the game with our concepts and what we were trying to d
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme